Key facts
- Nexsen (ASX: NXN)’s last known valuation is $29.6M (Oct 2025).
- It has raised $8.3M; the latest was IPO ($5.3M) in Oct 2025.
- Status: Publicly Held.
- ·Watchlist + deal alerts for Nexsen (ASX: NXN)
- ·The full record, as it builds
Funding rounds
No funding rounds for Nexsen (ASX: NXN) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nexsen (ASX: NXN)
Nexsen Ltd is a nanobiotechnology company for the development of biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications. Its products include: GBS Rapid Sensor, Chronic Kidney Disease (CKD), Bovine Mastitis, Acute Kidney Injury (AKI), and Biosecurity Pathogen Tests (x2).
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2021
- Employees
- 8
- Website
- nexsen.bio/
- Ownership
- Publicly Held
Nexsen (ASX: NXN) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nexsen (ASX: NXN) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nexsen (ASX: NXN) in its N-PORT filings yet. We sweep new filings monthly.